Endoglin: An accessory component of the TGF-β-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies

Journal of Cellular Physiology

Volumn 188, Issue 1, 2001, Pages 1-7

  Fonsatti, Ester ^a   Del Vecchio, Luigi ^b   Altomonte, Maresa ^a   Sigalotti, Luca ^a   Nicotra, Maria Rita ^c   Coral, Sandra ^a   Natali, Pier Giorgio ^d   Maio, Michele ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c CNR   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANGIOGENESIS; CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; ANTIGENS, CD; ENDOTHELIUM, VASCULAR; HUMANS; MACROMOLECULAR SUBSTANCES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0035017536     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.1095     Document Type: Review

References (53)

1. Adam PJ, Clesham GJ, Weissberg PL. 1998. Expression of endoglin mRNA and protein in human vascular smooth muscle cells. Biochem Biophys Res Commun 247:33-37.
2. Altomonte M, Montagner R, Fonsatti E, Colizzi F, Cattarossi I, Brasoveanu LI, Nicotra MR, Cattelan A, Natali PG, Maio M. 1996. Expression and structural features of endoglin (CD105), a transforming growth factor β1, and β3 binding protein, in human melanoma. Br J Cancer 74:1586-1591.
3. Barbara NP, Wrana JL, Letarte M. 1999. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J Biol Chem 274:584-594.
4. Bellón T, Corbi A, Lastres P, Cales C, Cebrian M, Vera S, Cheifetz S, Massague J, Letarte M, Bernabeu C. 1993. Identification and expression of two forms of the human transforming growth factor-β-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 23:2340-2345.
5. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. 1998a. Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma. Anticancer Res 18:2701-2710.
6. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. 1998b. Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neovascularization. Anticancer Res 18:3621-3628.
7. Bouck N, Stellmach V, Hsu SC. 1996. How tumors become angiogenic. Adv Cancer Res 69:135-174.
8. Bourdeau A, Dumont DJ, Letarte M. 1999. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 104:1343-1351.
9. Brasoveanu LI, Fonsatti E, Visintin A, Pavlovic M, Cattarossi I, Colizzi F, Gasparollo A, Coral S, Horejsi V, Altomonte M, Maio M. 1997. Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity. J Clin Invest 100:1248-1255.
10. Bredow S, Lewin M, Hofmann B, Marecos E, Weissleder R. 2000. Imaging of tumour neovasculature by targeting the TGF-β binding receptor endoglin. Eur J Cancer 36:675-681.
11. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES, Thorpe PE. 1995. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1:1623-1634.
12. Cheifetz S, Bellón T, Calés C, Vera S, Bernabeu C, Massagué J, Letarte M. 1992. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 267:19027-19030.
13. Derynck R, Feng XH. 1997. TGF-β receptor signaling. Biochim Biophys Acta 1333:F105-F150.
14. Fernández-Ruiz E, St-Jacques S, Bellón T, Letarte M, Bernabeu C. 1993. Assignment of the human endoglin gene (END) to 9q34→qter. Cytogenet Cell Genet 64:204-207.
15. Folkman J. 1989. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6.
16. Fonsatti E, Jekunen AP, Kairemo KJA, Coral S, Snellman M, Nicotra MR, Natali PG, Altomonte M, Maio M. 2000. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 6:2037-2043.
17. Gougos A, Letarte M. 1988. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 141:1925-1933.
18. Gougos A, Letarte M. 1990. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265:8361-8364.
19. Griffioen AW, Molema G. 2000. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52:237-268.
20. Guerrero-Esteo M, Lastres P, Letamendía A, Pérez-Alvarez MJ, Langa C, López LA, Fabra A, García-Pardo A, Vera S, Letarte M, Bernabéu C. 1999. Endoglin overexpression modulates cellular morphology, migration, and adhesion of mouse fibroblasts. Eur J Cell Biol 78:614-623.
21. Henriksen R, Gobl A, Wilander E, Öberg K, Miyazono K, Funa K. 1995. Expression and prognostic significance of TGF-β isotypes, latent TGF-β1 binding protein, TGF-β type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest 73:213-220.
22. Koff A, Ohtsuki M, Polyak K, Roberts JM, Massagué J. 1993. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science 260:536-539.
23. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, Bundred N. 1999. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59:856-861.
24. Lastres P, Bellon T, Cababas C, Sanchez-Madrid F, Acevedo A, Gougos A, Letarte M, Bernabéu C. 1992. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 22:393-397.
25. Lastres P, Martín-Perez J, Langa C, Bernabeu C. 1994. Phosphorylation of the human-transforming-growth-factor-β-binding protein endoglin. Biochem J 301:765-768.
26. Lastres P, Letamendía A, Zhang H, Rius C, Almendro N, Raab U, Lœpez LA, Langa C, Fabra A, Letarte M, Bernabéu C. 1996. Endoglin modulates cellular response to TGF-β1. J Cell Biol 133: 1109-1121.
27. Letamendía A, Lastres P, Botella LM, Raab U, Langa C, Velasco B, Attisano L, Bernabeu C. 1998a. Role of endoglin in cellular responses to transforming growth factor-β. J Biol Chem 273: 33011-33019.
28. Letamendía A, Lastres P, Almendro N, Raab U, Buhring H-J, Kumar S, Bernabéu C. 1998b. Endoglin, a component of the TGF-β receptor system, is a differentiation marker of human choriocarcmoma cells. Int J Cancer 76:541-546.
29. Letarte M, Greaves A, Vera S. 1995. CD105 (endoglin) cluster report. In: Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF, Todd RF, editors. Leucocyte typing V. White Cell Differentiation Antigens. Oxford, New York, Tokyo: Oxford University Press, p 1756-1759.
30. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, Wendel DP. 1999. Defective angiogenesis in mice lacking endoglin. Science 284:1534-1537.
31. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. 2000a. CD105 antagonizes the inhibitory signaling of transforming growth factor β1 on human vascular endothelial cells. FASEB J 14:55-64.
32. Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N, Kumar S. 2000b. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 89:122-126.
33. Lo Pardo C, Altomonte M, Boccuni P, Di Noto R, Vacca C, Maio M, Del Vecchio L. 1997. CD105 Workshop: Expression of CD105 on acute leukemia blast cells: application for minimal residual disease detection. In: Kishimoto T, Kikutani H, Kr von dem Borne AEG, Goyert SM, Mason DY, Miyasaka M, Moretta L, Okumura K, Shaw S, Springer TA, Sugamura K, Zola H, editors. Leucocyte typing VI. White Cell Differentiation Antigens. New York & London: Garland Publishing, Inc. p 711-712.
34. Luque A, Cababas C, Raab U, Letamendía A, Páez E, Herreros L, Sanchez-Madrid F, Bernabeu C. 1997. The use of recombinant vaccinia virus to generate monoclonal antibodies against the cell-surface glycoprotein endoglin. FEBS Lett 413:265-268.
35. Massagu J. 1990. The transforming growth factor-β family. Annu Rev Cell Biol 6:597-641.
36. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK. 1999. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 5:371-382.
37. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, McCormick MK, Pericak-Vance MA, Heutink P, Oostra BA, Haitjema T, Westerman CJJ, Porteous ME, Guttmacher AE, Letarte M, Marchuk DA. 1994. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8:345-351.
38. Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A, Sedlacek H-H, Mller R, Adamkiewicz J. 1999. Elevated expression of endoglin, a component of the TGF-β-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 81:568-572.
39. O'Connell PJ, McKenzie A, Fisicaro N, Rockman SP, Pearse MJ, d'Apice AJF. 1992. Endoglin: A 180-kD endothelial cell and macrophage restricted differentiation molecule. Clin Exp Immunol 90:154-159.
40. low/- precursors. Br J Haematol 108:610-620.
41. Qu R, Silver MM, Letarte M. 1998. Distribution of endoglin in early human development reveals high levels on endocardial cushion tissue mesenchyme during valve formation. Cell Tissue Res 292:333-343.
42. Roberts AB, Sporn MB. 1993. Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factor 8:1-9.
43. Robledo MM, Hidalgo A, Lastres P, Arroyo AG, Bernabeu C, Sanchez-Madrid F, Teixido J. 1996. Characterization of TGF-β 1 binding proteins in human bone marrow stromal cells. Br J Haematol 93:507-514.
44. Rokhlin OW, Cohen MB, Kubagawa H, Letarte M, Cooper MD. 1995. Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J Immunol 154:4456-4465.
45. Ríus C, Smith JD, Almendro N, Langa C, Botella LM, Marchuk DA, Vary CPH, Bernabéu C. 1998. Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. Blood 92:4677-4690.
46. Seon BK, Matsuno F, Haruta Y, Barcos M, Spaulding B. 1997a. CD105 Workshop: Immunohistochemical detection of CD105 in the vascular endothelium of human malignant and non-malignant tissues. In: Kishimoto T, Kikutani H, Kr von dem Borne AEG, Goyert SM, Mason DY, Miyasaka M, Moretta L, Okumura K, Shaw S, Springer TA, Sugamura K, Zola H, editors. Leucocyte typing VI. White Cell Differentiation Antigens. New York & London: Garland Publishing, Inc. p 709-711.
47. Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M. 1997b. Longlasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 3:1031-1044.
48. 125I-labeled anti-endoglin monoclonal antibodies. Int J Cancer 82:737-742.
49. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD. 1993. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 54:363-370.
50. Wang JM, Wilson PB, Kumar S, Pye D, Hunter RD. 1994a. Quantitation of endothelial cell specific protein E-9 employing a single monoclonal antibody in an indirect sandwich ELISA. J Immunol Methods 171:55-64.
51. Wang JM, Kumar S, Pye D, Haboubi N, Al-Nakib L. 1994b. Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. J Natl Cancer Inst 86:386-388.
52. Yamashita H, Ichijo H, Grimsby S, Morén A, ten Dijke P, Miyazono K. 1994. Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-β. J Biol Chem 269:1995-2001.
53. Yang YE, Moses HL. 1990. Transforming growth factor β1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 111:731-741.